emitefur has been researched along with Stomach Neoplasms in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (66.67) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Fujita, F; Fujita, M; Inaba, H; Taguchi, T | 1 |
Maehara, Y; Sugimachi, K | 1 |
Fujii, S; Fujita, F; Fujita, M; Fukushima, M; Shirasaka, T; Taguchi, T | 1 |
1 trial(s) available for emitefur and Stomach Neoplasms
Article | Year |
---|---|
A phase II trial of a new 5-fluorouracil derivative, BOF-A2 (Emitefur), for patients with advanced gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Disease Progression; Female; Fluorouracil; Humans; Male; Middle Aged; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2000 |
2 other study(ies) available for emitefur and Stomach Neoplasms
Article | Year |
---|---|
[Antitumor activity of BOF-A2, a new 5-fluorouracil derivative, against human cancers xenografted in nude mice by intermittent administration].
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Stomach Neoplasms; Tegafur; Uracil | 1993 |
[Antitumor activity and metabolism of BOF-A2, a new 5-fluorouracil derivative, with human cancers xenografted in nude mice].
Topics: Administration, Oral; Animals; Antineoplastic Agents; Colorectal Neoplasms; Fluorouracil; Humans; Liver; Mice; Mice, Nude; Microsomes; Neoplasm Transplantation; Neoplasms, Experimental; Pancreatic Neoplasms; Stomach Neoplasms | 1990 |